First in Human Dosing of HT-6184, a Novel Allosteric NEK7 Inhibitor Targeting NLRP3 Assembly & Function

Time: 12:00 pm
day: Day 2 - Track B - Morning

Details:

  • Explore how targeting the ability of Nek7 to bind to NLRP3 blocks and activation and promotes disassembly of the NLRP3 Inflammasome
  • Review how HT-6184 potently blocks NLRP3 activity and function
  • Evaluate data on the PK and PD of HT-6184 in the firstin- human trial that will be presented

Speakers: